The Company
The Company
Projects
Projects
Investors
Investors
Corporate Governance
Corporate Governance
Media
Media
Contact
Contact
- - Office
- - Investors
- - Media

Svenska

Promore Pharma in Brief
Vision and Strategy
Market
Team
Board of Directors

Project Overview
Ensereptide – Prevention of Scarring
Ropocamptide – Healing of Chronic Wounds
Publications

Promore Pharma on Nasdaq First North Growth Market
- Certified Adviser
The Share
Financial Reports
Press Releases
Prospectuses
Presentations and Events
Calendar
Subscribe

Corporate Governance

Corporate Governance
General Meeting
- General Meetings
Nomination Committee
- Nomination Committees
The Board of Directors
- Board of Directors
The Management
- Management
Remunerations and Remuneration Committee
Auditor and Audit Committee
Articles of Association
Certificate of Registration

Press Releases
Imagebank
Promore Pharma in Media
Subscribe

Office
Investors
Media

Media

Press Releases
Imagebank
Promore Pharma in Media
Subscribe

Contact

Chief Financial Officer (CFO) +46 70 856 52 45

Promore Pharma in Media

2023

2022
2021
All years

January 10, 2023

Promore Pharma’s CEO on hopes for 2023 – BioStock

Promore Pharma in Brief
Vision and Strategy
Market
Team
Board of Directors

Project Overview
Ensereptide – Prevention of Scarring
Ropocamptide – Healing of Chronic Wounds
Publications

Promore Pharma on Nasdaq First North Growth Market
The Share
Financial Reports
Press Releases
Prospectuses
Presentations and Events
Calendar
Subscribe

Corporate Governance

Corporate Governance
General Meeting
Nomination Committee
The Board of Directors
The Management
Remunerations and Remuneration Committee
Auditor and Audit Committee
Articles of Association
Certificate of Registration

Press Releases
Imagebank
Promore Pharma in Media
Subscribe

Office
Investors
Media

Promore Pharma AB. Address: Fogdevreten 2, SE-171 65 Solna, Sweden. Phone: +46 8 124 548 59. E-mail: info@promorepharma.com. Registration number: 556639-6809.

Personal data
About cookies